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by Elsevier B.V. All rights reserved.Liver deterioration as a consequence of injury and inﬂammation
becomes counteracted by active organogenic regeneration. The
cellular origin of regeneration depends on the duration of disease.
Acute and early stages of chronic hepatitis result in the transient
proliferation of organ-resident hepatocytes. Chronic and long-
lasting hepatitis exhausts this proliferative potential and induces
senescence. Thereafter, regeneration is conducted by tissue stem
cells via transit amplifying and differentiating cells. Human liver
stem cells in chronic hepatitis manifest as ductular reactions
(DR), which represent potential intrahepatic, hepatobiliary tissue
stem cells. Yoon et al. reported on DR being tissue stem/progen-
itor compartments and regenerative areas [1], which were
characterised by strong cytoplasmic staining of epithelial cell
adhesion molecule EpCAM. Along with hepatocellular differenti-
ation, cells increasingly shifted EpCAM localisation from
cytoplasmic to membranous. Transit-amplifying cells were char-
acterised by intermediate EpCAM expression, proliferation, and
telomere length, ranging between DR cells and differentiated
EpCAM-negative hepatocytes (Fig. 1A). Data by Yoon et al. clearly
speak in favour of a hierarchically structured regeneration of the
liver based on differentiation processes, rather than a transient
proliferation of pre-existing hepatocytes during late stages of
the disease.
The EpCAMhigh phenotype in bipotential hepatoblast precur-
sors and changes of EpCAM expression along with hepatocellular
differentiation traits are of utmost interest in light of the reported
adhesive, signalling, and proliferative properties of EpCAM in
cancer, normal progenitor cells, and in tumour-initiating cellsJournal of Hepatology 20
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mostly lack EpCAM, except for cells of the basal layer, which rep-
resent the less differentiated cells with residual proliferation
capacity. Embryonic stem cells (ES), induced-pluripotency stem
cells, and tissue progenitors of various organs including liver, kid-
ney, mammary gland, and hair follicle highly express EpCAM at
plasma membranes, and downregulate it once organo- and mor-
phogenesis is completed [3–9]. In ES cells, EpCAM is essential for
maintenance of pluripotency and proliferation, and more gener-
ally, is endowed with dual functions as a homophilic cell adhe-
sion molecule [10] and a receptor, which is activated upon
regulated intramembrane proteolysis [11] (Fig. 1B). Proteolytic
cleavage generates an intracellular signalling domain (EpICD),
which uses components of the Wnt signalling pathway (i.e.
FHL2, b-catenin, Lef-1), activates promoters of stemness genes
including c-Myc, Sox2, Nanog, Oct4, and KLF4 [5,11] and is
required for proliferation of EpCAM-positive cells [11–13]. Differ-
ences between normal and malignant cells have been reported
for epithelia of the colon and colon carcinomas, with a tumour-
associated cleavage and nuclear translocation of EpICD [11]. Thus,
EpCAMhigh in hepatocellular progenitor/stem cells potentially
empowers them with pluripotency and proliferative traits, while
declining expression in transit-amplifying cells might be sufﬁ-
cient to disconnect cells from multipotency programs but still
drive transient proliferation. Differentiated hepatocytes do not
or barely express EpCAM and will accordingly lack signals related
to both, stemness and proliferation.
Cytoplasmic localisation of EpCAM in hepatocellular progen-
itors as reported by Yoon et al. is, however, intriguing. EpCAM
expression in normal, cancer, and stem cells was predomi-
nantly or even exclusively observed at the plasma membrane,
where signalling initiates [11,12]. An alternative scenario is
conceivable in which EpCAM signalling towards multipotency
and proliferation initiates within DR cells at intracellular mem-
branes, while its presence at plasma membranes rather associ-
ates with adhesive functions (Fig. 1). This would allow for
balanced regulation of proliferation, differentiation, and cell
adhesion along differentiation cascades from DR to mature
hepatocytes. In this respect, assessment of the subcellular
localisation of the signalling domain of EpCAM (EpICD) in the
various cell types of chronically injured liver would shed light
on these open questions and provide experimental evidence for














































Fig. 1. Potential functions of EpCAM in hepatocellular regeneration. (A) Schematic representation of differentiation and EpCAM expression in hepatocellular
regeneration. (B) Schematic representation of EpCAM functions in cell adhesion, proliferation, and regulation of pluripotency. Left panel, EpCAM is a homophilic cell
adhesion molecule expressed at the basolateral membranes of healthy epithelia, where it confers weak cell-to-cell adhesion. EpCAM is linked to the cytoskeleton via its
interaction with a-actinin. Right panel, EpCAM is a signalling active receptor, which becomes activated upon regulated intramembrane proteolysis through TACE and
gamma secretase. The shed ektodomain EpEX serves as a ligand for intact EpCAM molecules. Intracellular domain EpICD interacts with FHL2 and b-catenin to translocate
into the nucleus and contact DNA via interactions with Lef-1 to induce gene transcription.
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